Entering text into the input field will update the search result below

Novo's semaglutide beats Lilly's dulaglutide in late-stage study in type 2 diabetics; shares ahead 3%

Aug. 16, 2017 3:05 PM ETNovo Nordisk A/S (NVO) StockNVO, LLYBy: Douglas W. House, SA News Editor4 Comments
  • Novo Nordisk (NVO +2.9%) is up at Eli Lilly's (LLY -0.9%) expense after it announced results from the Phase 3b SUSTAIN 7 study comparing glucose control and weight loss in type 2 diabetics treated with either once-weekly semaglutide or Lilly's once-weekly Trulicity (dulaglutide) over 40 weeks.
  • From a mean baseline HbA1c of 8.2%, patients receiving 0.5 mg of semaglutide achieved a statistically significant reduction of 1.5% compared to 1.1% for 0.75 mg of dulaglutide. Patients receiving 1.0 mg of semaglutide experienced a reduction of 1.8% versus 1.4% for 1.5 mg of dulaglutide.
  • The percentages of patients achieving their target HbA1c levels or below for the lower and higher doses of semaglutide and dulaglutide were 69%/52% and 79%/68%, respectively.
  • On the weight loss front, patients treated with 0.5 mg and 1.0 mg of semaglutide experienced mean weight loss of 4.6 kg and 6.5 kg, respectively. Patients receiving 0.75 mg and 1.5 mg of dulaglutide lost an average of 2.3 kg and 3.0 kg, respectively.
  • The percentages of patients who lost at least 5% of their body weight in the two doses of semaglutide were 44% and 63%, respectively, compared to 30% for 1.5 mg of dulaglutide.
  • Novo's marketing applications for semaglutide are currently under review in seven jurisdictions, including the U.S., EU and Japan.
  • Previously: Novo submits U.S. marketing application for long-acting diabetes med semaglutide in T2D (Dec. 5, 2016)

This was corrected on 02/06/2019 at 2:26 AM. Weight loss effects clarified. There were only two doses of semaglutide tested, 0.5 mg and 1.0 mg.

Recommended For You

About NVO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVO--
Novo Nordisk A/S